Peptide library / Digestive & weight / Survodutide
Survodutide
An investigational dual glucagon and GLP-1 receptor agonist being developed for obesity and fatty liver disease.
Effects studied or claimed
What it is used or promoted for, and where each effect has actually been seen
- Weight loss in obesityLarge trials
- Metabolic dysfunction-associated steatohepatitis (MASH)Small human studies
How it is thought to work
Survodutide combines appetite suppression through GLP-1 with glucagon signaling in the liver, which may reduce liver fat and raise energy use.
What the evidence shows
A phase 2 obesity trial reported dose-dependent weight loss, and a phase 2 liver trial showed improvement in liver fat and inflammation scores. Boehringer Ingelheim is running phase 3 programs in obesity and MASH.
Safety and unknowns
Nausea, vomiting and diarrhea were the most common effects and were the main reason for discontinuation at higher doses.
Regulatory status
Not approved. Development is in phase 3.
Regulatory status changes quickly. This entry was last reviewed on 27 October 2026. Confirm current status with the FDA before relying on it.
More in Digestive & weight
Teduglutide
FDA-approvedA GLP-2 analog that helps the gut absorb nutrients in short bowel syndrome.
Tirzepatide
FDA-approvedA once-weekly dual GIP and GLP-1 receptor agonist approved for type 2 diabetes, obesity and sleep apnea in obesity.
Sincalide
FDA-approvedA synthetic fragment of the gut hormone cholecystokinin used in gallbladder and pancreas tests.
General information, not medical advice. Do not buy or inject unregulated peptides.